

- **Name:** Antoine Italiano
- **Current Position & Affiliation:** DITEP, Gustave Roussy
- **Country:** France

• **Educational Background:**

Degree (include field of study)	Institution name & Location	Dates attended (mm/yy - mm/yy)	Year Award ed
PhD Molecular Genetics	University of Nice, France thesis advisors Florence PEDEUTOUR PharmD PhD ; Thesis “Molecular cytogenetics of Adipocyt Tumors”	06/2005- 01/2008	2008
MD	University of Nice, France	10/97-10/2008	2008

• **Professional Experience:**

Title	Institution, city and state	Dates (mm/yy - mm/yy)
Full Professor of Medicine	University of Bordeaux, Bordeaux, France	09/16-present
Attending Physician	Gustave Roussy, Villejuif, France	03/20-Present

• **Professional Organizations:**

American Society of Clinical Oncology
American Association for Cancer Research
European Society of Medical Oncology (ESMO)
French Sarcoma Group (GSF/GETO)

• **Main Scientific Publications:**

1. El Ghazzi N, **Italiano A**, Bay JO, Dougé A. Développement des CAR-T cells dans les tumeurs solides [CAR-T cells development in solid tumors]. Bull Cancer. 2023 Jan;110(1):32-41. French. doi: 10.1016/j.bulcan.2022.12.001. Epub 2022 Dec 19. PMID: 36543680.
2. Cousin S, Toulmonde M, Kind M, Guegan JP, Bessede A, Cantarel C, Bellera C, **Italiano A**. Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer. Exp Hematol Oncol. 2022 Dec 6;11(1):104. doi: 10.1186/s40164-022-00338-2. PMID: 36474303; PMCID: PMC9724410.

3. Spalato Ceruso M, Toulmonde M, Blouin L, **Italiano A**. Circulating tumour DNA sequencing reveal mechanisms of resistance to BRAF-targeted therapies in BRAF-mutated gastrointestinal stromal tumour. *Eur J Cancer*. 2023 Jan;179:25-27. doi:10.1016/j.ejca.2022.10.018. Epub 2022 Nov 1. PMID: 36470024.
4. Martin-Romano P, Mezquita L, Hollebecque A, Lacroix L, Rouleau E, Gazzah A, Bahleda R, Planchard D, Varga A, Baldini C, Postel-Vinay S, Friboulet L, Loriot Y, Verlingue L, Geraud A, Camus MN, Nicotra C, Soria JC, André F, Besse B, Massard C, **Italiano A**. Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology. *JCO Precis Oncol*. 2022 Oct;6:e2100484. doi: 10.1200/PO.21.00484. PMID: 36315916.
5. Spalato-Ceruso M, Bouteiller F, Guegan JP, Toulmonde M, Bessede A, Kind M, Cousin S, Buy X, Palussiere J, Le Loarer F, Dadone-Montaudie B, Pulido M, **Italiano A**. Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study. *J Hematol Oncol*. 2022 Oct 27;15(1):157. doi: 10.1186/s13045-022-01377-2. PMID: 36303228; PMCID: PMC9609223.
6. Toulmonde M, Cousin S, Kind M, Guegan JP, Bessede A, Le Loarer F, Perret R, Cantarel C, Bellera C, **Italiano A**. Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma. *J Hematol Oncol*. 2022 Oct 21;15(1):149. doi:10.1186/s13045-022-01370-9. PMID: 36271420; PMCID: PMC9585864.
7. Crombé A, Roulleau-Dugage M, **Italiano A**. The diagnosis, classification, and treatment of sarcoma in this era of artificial intelligence and immunotherapy. *Cancer Commun (Lond)*. 2022 Dec;42(12):1288-1313. doi: 10.1002/cac2.12373. Epub 2022 Oct 19. PMID: 36260064; PMCID: PMC9759765.
8. Bayle A, Peyraud F, Belcaid L, Brunet M, Aldea M, Clodion R, Dubos P, Vasseur D, Nicotra C, Geraud A, Sakkal M, Cerbone L, Blanc-Durand F, Mosele F, Martin Romano P, Ngo Camus M, Soubeyran I, Khalifa E, Alame M, Blouin L, Dinart D, Bellera C, Hollebecque A, Ponce S, Loriot Y, Besse B, Lacroix L, Rouleau E, Barlesi F, Andre F, **Italiano A**. Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM). *Ann Oncol*. 2022 Dec;33(12):1328-1331. doi: 10.1016/j.annonc.2022.08.089. Epub 2022 Sep 17. PMID: 36122799.